[Previous Months][Date Index][Thread Index][Join - Register][Login]
[Message Prev][Message Next][Thread Prev][Thread Next]

[IP] Glucowatch has been approved in Europe

I just received a news release indicating that Cygnus has received 
approval for the GlucoWatch in Europe.  It still will be a while before 
the FDA approves it for USA sales but it would appear that it is a good 
sign that we may soon have a less invasive method for blood sugar 
monitoring in the not-too-distant future.  The text of the release from 
Cygnus follows and includes information about the FDA approval process:

  Cygnus` GlucoWatch(R) Monitor Approved for Sale 
in Europe 		
 			Article Found In		Quick Search	
REDWOOD CITY, Calif., Dec. 2 /PRNewswire/ via NewsEdge Corporation -- Cygnus, Inc. 
(Nasdaq: CYGN) announced today the receipt of a CE Certificate for the 
GlucoWatch(R) monitor, indicating that the product has met the essential requirements 
and other criteria of the European Community Directive 93/42/ECC, Annex V, Section 
3.2. The CE Certificate is required for selling products in the European Community. 
Cygnus demonstrates compliance to BS EN ISO 9002 and EN 46002.  "Receiving the CE 
Certificate is another important step in the progress of the GlucoWatch monitor. The 
quality standards and processes required to receive the CE Certificate will serve us 
well in the future," stated John C. Hodgman, Chairman, President and Chief Executive 
Officer of Cygnus, Inc.  The GlucoWatch monitor provides frequent, automatic and 
non-invasive glucose measurements and is intended for detecting trends and tracking 
patterns in glucose levels in adults, 18 years and older, who have diabetes. The device 
is intended for use by patients at home and in health care facilities. Following a three-
hour warm-up period, the device is capable of providing up to three non-invasive 
glucose measurements per hour for 12 hours. After the warm-up period, a finger stick 
blood glucose measurement is input into the GlucoWatch monitor for calibration. The 
frequent readings provided by the GlucoWatch monitor have the potential to help 
people with diabetes to better control their glucose levels. The GlucoWatch monitor 
has the capability to alert users when glucose levels are too high or too low. These 
situations may be hard to identify with regular glucose testing alone.  The United 
States Food and Drug Administration (FDA) has scheduled December 6, 1999 as the 
date for an advisory committee review of Cygnus' premarket approval application 
(PMA) for the GlucoWatch monitor. The meeting will be held with the Clinical Chemistry 
and Clinical Toxicology Devices Panel of the Medical Devices Advisory Committee at 
the Gaithersburg Marriott Washingtonian Center, 9751 Washingtonian Boulevard, 
Gaithersburg, Maryland.  Cygnus is currently seeking an alliance for the 
commercialization of the GlucoWatch monitor worldwide (except Japan and Korea) 
which would include distribution, sales, marketing, and customer service support. 
Tokyo-based Yamanouchi Pharmaceutical Co., Ltd., a significant participant in the 
Japanese pharmaceutical market, has marketing and distribution rights for the 
GlucoWatch monitor in Japan and Korea.  Cygnus is engaged in the development and 
manufacture of diagnostic and drug delivery systems utilizing its proprietary 
technologies to satisfy unmet medical needs cost effectively. Cygnus' current efforts 
are primarily focused on two core areas: a frequent, automatic and non-invasive 
glucose monitoring device (the GlucoWatch device) and transdermal drug delivery 
systems. Cygnus has signed a binding agreement to sell most of the assets of its drug 
delivery business to Ortho-McNeil Pharmaceutical, Inc, a Johnson & Johnson company.  
This news release contains forward-looking statements regarding future events and 
the future performance of the Company that involve risks and uncertainties that may 
cause the Company's actual results to differ materially. Such factors include the 
government approvals, commercial introduction and market acceptance of the 
GlucoWatch monitor. There can be no assurances that the panel meeting will result in 
a recommendation for approval to the FDA. There can be no assurances that a 
recommendation for approval from the advisory committee would result in a clearance 
from the FDA to market the device. There can be no assurances that the Company will 
be able to sign a marketing agreement. Also, there can be no assurances that if the 
Company receives marketing clearance from the FDA and signs a marketing agreement 
that the product could be successfully manufactured or marketed in the U.S. or in 
Europe. Further, there can be no assurances that the proposed asset sale of the drug 
delivery business will pass governmental review under the Hart-Scott-Rodino 
Improvements Act of 1976. The Company refers you to the documents the Company 
files from time to time with the Securities and Exchange Commission, including the 
Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current 
Reports on Form 8-K, which contain descriptions of certain factors that could cause 
the Company's actual results to differ from the Company's current expectations and 
any forward-looking statements contained in this news release.  SOURCE Cygnus, Inc.  
/CONTACT: Cygnus, Inc. Corporate Communications, 650-369-4300; or press, Justin 
Jackson of Burns McClellan, 212-213-0006, for Cygnus/ /Web site: 
http://www.cygn.com/ (CYGN) 	

for HELP or to subscribe/unsubscribe, contact: HELP@insulin-pumpers.org
send a DONATION http://www.Insulin-Pumpers.org/donate.shtml